Jaguar Health Beheer
Beheer criteriumcontroles 4/4
De CEO Jaguar Health is Lisa Conte, benoemd in Jun2013, heeft een ambtstermijn van 11.42 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 815.85K, bestaande uit 70.6% salaris en 29.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.18% van de aandelen van het bedrijf, ter waarde $ 17.29K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.9 jaar en 6.7 jaar.
Belangrijke informatie
Lisa Conte
Algemeen directeur
US$815.9k
Totale compensatie
| Percentage CEO-salaris | 70.6% |
| Dienstverband CEO | 11.4yrs |
| Eigendom CEO | 0.2% |
| Management gemiddelde ambtstermijn | 3.9yrs |
| Gemiddelde ambtstermijn bestuur | 6.7yrs |
Recente managementupdates
Recent updates
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27%
Nov 09
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27%
Nov 09Jaguar Health, Inc. (NASDAQ:JAGX) Stock's 55% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Jul 24Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 49%
May 24Jaguar Health, Inc. (NASDAQ:JAGX) Shares Fly 55% But Investors Aren't Buying For Growth
Mar 29Jaguar Health, Inc. (NASDAQ:JAGX) Not Doing Enough For Some Investors As Its Shares Slump 39%
Jan 22Positive Sentiment Still Eludes Jaguar Health, Inc. (NASDAQ:JAGX) Following 32% Share Price Slump
Jun 10Jaguar Health (NASDAQ:JAGX) Is Carrying A Fair Bit Of Debt
Jan 23Jaguar Health rises 19% on orphan drug tag for congenital diarrheal disorder treatment
Oct 17Jaguar Health sells crofelemer and lechlemer royalty rights for $4M upfront
Aug 25Jaguar Health gets 180-day grace period to regain compliance with Nasdaq's listing rule
Aug 19Jaguar Health rises on U.S. patent for treating chemotherapy-induced diarrhea
Aug 09Jaguar stock rises on license deal with SynWorld for Canalevia in China
Jun 29Jaguar Health CEO Lisa Conte - From Rainforest To Laboratory
Mar 07Jaguar Health shares jumps 13% after pricing $15M direct offering
Jan 13Jaguar Health plans for conditional marketing application in Europe for Crofelemer, initially for Long-Hauler COVID-19 patients
Jan 11Jaguar Health leaps higher in new year
Jan 05Jaguar Health inks second Mytesi royalties agreement for $6M
Dec 23Does Jaguar Health (NASDAQ:JAGX) Have A Healthy Balance Sheet?
Dec 02
Jaguar Health's crofelemer development nears SPAC funding in Europe, shares +61%
Nov 30Jaguar Health EPS misses by $0.10, misses on revenue
Nov 16Jaguar Health receives positive Nasdaq listing determination
Oct 29Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$38m |
| Jun 30 2024 | n/a | n/a | -US$36m |
| Mar 31 2024 | n/a | n/a | -US$38m |
| Dec 31 2023 | US$816k | US$576k | -US$41m |
| Sep 30 2023 | n/a | n/a | -US$40m |
| Jun 30 2023 | n/a | n/a | -US$44m |
| Mar 31 2023 | n/a | n/a | -US$42m |
| Dec 31 2022 | US$1m | US$603k | -US$47m |
| Sep 30 2022 | n/a | n/a | -US$54m |
| Jun 30 2022 | n/a | n/a | -US$54m |
| Mar 31 2022 | n/a | n/a | -US$59m |
| Dec 31 2021 | US$3m | US$527k | -US$53m |
| Sep 30 2021 | n/a | n/a | -US$50m |
| Jun 30 2021 | n/a | n/a | -US$46m |
| Mar 31 2021 | n/a | n/a | -US$42m |
| Dec 31 2020 | US$1m | US$500k | -US$39m |
| Sep 30 2020 | n/a | n/a | -US$35m |
| Jun 30 2020 | n/a | n/a | -US$39m |
| Mar 31 2020 | n/a | n/a | -US$45m |
| Dec 31 2019 | US$1m | US$500k | -US$45m |
| Sep 30 2019 | n/a | n/a | -US$48m |
| Jun 30 2019 | n/a | n/a | -US$43m |
| Mar 31 2019 | n/a | n/a | -US$34m |
| Dec 31 2018 | US$1m | US$480k | -US$32m |
| Sep 30 2018 | n/a | n/a | -US$41m |
| Jun 30 2018 | n/a | n/a | -US$30m |
| Mar 31 2018 | n/a | n/a | -US$24m |
| Dec 31 2017 | US$643k | US$440k | -US$22m |
Compensatie versus markt: De totale vergoeding ($USD 815.85K ) Lisa } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 650.80K ).
Compensatie versus inkomsten: De vergoeding van Lisa is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Lisa Conte (65 yo)
11.4yrs
Tenure
US$815,854
Compensatie
Ms. Lisa A. Conte serves as a Scientific Advisor at Triton Funds LLC. She is a Former Member of Scientific Advisory Board at Triton Funds LLC. She founded Jaguar Health, Inc. (formerly known as Jaguar Anim...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 11.4yrs | US$815.85k | 0.18% $ 17.3k | |
| Chief Scientific Officer & Chair of Scientific Advisory Board | 2.7yrs | US$627.13k | 0.054% $ 5.2k | |
| Chief of Staff | 6yrs | US$562.79k | 0.054% $ 5.2k | |
| Chief of Sustainable Supply | 10.2yrs | US$491.54k | 0.054% $ 5.1k | |
| Chief Financial Officer | 4.7yrs | geen gegevens | 0.046% $ 4.5k | |
| Senior Director of Investor Relations | no data | geen gegevens | geen gegevens | |
| Executive VP of Corporate & Business Development | 3.2yrs | geen gegevens | geen gegevens | |
| Chief Manufacturing Officer | no data | geen gegevens | geen gegevens | |
| Chief Commercial Officer | 3.9yrs | US$557.90k | geen gegevens | |
| President of Jaguar International | less than a year | geen gegevens | geen gegevens | |
| Senior Vice President of Growth Strategy | less than a year | geen gegevens | geen gegevens | |
| Chief Medical Officer | no data | geen gegevens | geen gegevens |
3.9yrs
Gemiddelde duur
62yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van JAGX wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 11.4yrs | US$815.85k | 0.18% $ 17.3k | |
| Chief Scientific Officer & Chair of Scientific Advisory Board | 7.5yrs | US$627.13k | 0.054% $ 5.2k | |
| Independent Chairman | 10.8yrs | US$140.98k | 0.00041% $ 39.4 | |
| Independent Director | 8.6yrs | US$101.68k | 0.00024% $ 23.1 | |
| Independent Director | 2.3yrs | US$77.61k | 0.00031% $ 29.8 | |
| Independent Director | 6.7yrs | US$104.18k | 0.00026% $ 25.0 | |
| Member of Scientific Advisory Board | 1.8yrs | geen gegevens | geen gegevens | |
| Scientific Advisory Board | 1.7yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 1.5yrs | geen gegevens | geen gegevens |
6.7yrs
Gemiddelde duur
66yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van JAGX wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.7 jaar).